STING1 and neoplasm: Radiotherapy-induced DNA damage leads to interferon production via the cyclic GMP-AMP synthase (cGAS) / stimulator of interferon genes (STING) pathway, potentially inducing an anti-tumor immune response, with an optimal dose range around 8–10 Gy per fraction to obtain synergy between radiotherapy and anti-CTLA4/antiPDL-1 [12].